BR112015029776A2 - proteína quimérica, complexo proteico oligomérico, polinucleotídeo, vetor, célula transgênica, composição farmacêutica, método de produção da proteína quimérica, método para produzir um anticorpo, método de redução da carga bacteriana, método de indução de resistência, vacina, uso da proteína quimérica, anticorpo policlonal, método de prevenção e uso do anticorpo - Google Patents

proteína quimérica, complexo proteico oligomérico, polinucleotídeo, vetor, célula transgênica, composição farmacêutica, método de produção da proteína quimérica, método para produzir um anticorpo, método de redução da carga bacteriana, método de indução de resistência, vacina, uso da proteína quimérica, anticorpo policlonal, método de prevenção e uso do anticorpo

Info

Publication number
BR112015029776A2
BR112015029776A2 BR112015029776A BR112015029776A BR112015029776A2 BR 112015029776 A2 BR112015029776 A2 BR 112015029776A2 BR 112015029776 A BR112015029776 A BR 112015029776A BR 112015029776 A BR112015029776 A BR 112015029776A BR 112015029776 A2 BR112015029776 A2 BR 112015029776A2
Authority
BR
Brazil
Prior art keywords
antibody
chimeric protein
chimeric polypeptides
chimeric
vaccine
Prior art date
Application number
BR112015029776A
Other languages
English (en)
Other versions
BR112015029776B1 (pt
Inventor
Alberto Goldbaum Fernando
Ghersi Giselle
Veronica Bentancor Leticia
Pilar Mejias Maria
Sandra Palermo Marina
Diego Linus Spatz Martín
Oliver Craig Patricio
Zylberman Vanesa
Original Assignee
Inmunova S A
Martin Diego Linus Spatz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmunova S A, Martin Diego Linus Spatz filed Critical Inmunova S A
Publication of BR112015029776A2 publication Critical patent/BR112015029776A2/pt
Publication of BR112015029776B1 publication Critical patent/BR112015029776B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01078—6,7-Dimethyl-8-ribityllumazine synthase (2.5.1.78)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo quimeras de lumazina sintase de brucella e subunidade beta das toxinas ab5 a presente invenção refere-se aos polipeptídeos quiméricos úteis como imunógenos para induzir respostas imunoprotetoras e neutralizar anticorpos contra a toxina de shiga (stx) em mamíferos. mais especificamente, a presente invenção refere-se aos polipeptídeos quiméricos que compreendem um monômero da subunidade b hemopentamérica da toxina de shiga do tipo 2 fundida ao n-terminal de um monômero da lumazina sintase de brucella e aos complexos proteicos oligoméricos formados a partir dos ditos polipeptídeos quiméricos. a invenção refere-se ainda aos polinucleotídeos e vetores que codificam os ditos polipeptídeos quiméricos, às células transgênicas compreendendo os ditos polinucleotídeos e vetores, e às composições farmacêuticas, como uma vacina, compreendendo os ditos polipeptídeos quiméricos e os polinucleotídeos quiméricos. também estão dentro do escopo da invenção os anticorpos que se ligam aos polipeptídeos quiméricos da invenção, um método para a obtenção de anticorpos que se ligam especificamente à subunidade b da toxina de shiga do tipo 2 e métodos de redução da carga bacteriana de escherichi coli entero-hemorrágica em mamíferos, que podem ser usados para a prevenção, entre outras coisas, da síndrome hemolítico-uremica (hus).
BR112015029776-5A 2013-05-27 2014-05-26 Proteína quimérica, complexo proteico oligomérico, polinucleotídeo, vetor, célula transgênica, composição farmacêutica, método de produção da proteína quimérica e vacina BR112015029776B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827713P 2013-05-27 2013-05-27
US61/827713 2013-05-27
PCT/IB2014/061731 WO2014191903A1 (en) 2013-05-27 2014-05-26 Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins

Publications (2)

Publication Number Publication Date
BR112015029776A2 true BR112015029776A2 (pt) 2017-09-26
BR112015029776B1 BR112015029776B1 (pt) 2023-02-07

Family

ID=51136520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029776-5A BR112015029776B1 (pt) 2013-05-27 2014-05-26 Proteína quimérica, complexo proteico oligomérico, polinucleotídeo, vetor, célula transgênica, composição farmacêutica, método de produção da proteína quimérica e vacina

Country Status (10)

Country Link
US (1) US10633639B2 (pt)
EP (1) EP3003348B1 (pt)
JP (1) JP6674603B2 (pt)
CN (1) CN105555293B (pt)
AR (2) AR096444A1 (pt)
BR (1) BR112015029776B1 (pt)
CA (1) CA2913702C (pt)
ES (1) ES2749120T3 (pt)
MX (1) MX368441B (pt)
WO (2) WO2014191903A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191903A1 (en) 2013-05-27 2014-12-04 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
CN109196104B (zh) * 2016-04-11 2023-01-31 生源霸科乌拉圭有限公司 用于病毒性疾病的广效型疫苗
KR102625929B1 (ko) * 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1079856T3 (da) * 1998-05-20 2006-12-04 Teijin Ltd Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
AR044603A1 (es) 2004-06-03 2005-09-21 Consejo Nac Invest Cient Tec Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones
EP2007602A4 (en) * 2006-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
CN102532324B (zh) * 2010-12-30 2014-02-19 青岛红桥明勤生物科技有限公司 布氏杆菌基因工程亚单位疫苗的制备及其应用
WO2014191903A1 (en) 2013-05-27 2014-12-04 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins

Also Published As

Publication number Publication date
MX2015016347A (es) 2016-07-20
US20160115459A1 (en) 2016-04-28
WO2014191904A1 (en) 2014-12-04
ES2749120T3 (es) 2020-03-19
AR096444A1 (es) 2015-12-30
CA2913702C (en) 2023-08-01
BR112015029776B1 (pt) 2023-02-07
AR096445A1 (es) 2015-12-30
EP3003348B1 (en) 2019-07-10
CA2913702A1 (en) 2014-12-04
JP2016522209A (ja) 2016-07-28
WO2014191903A1 (en) 2014-12-04
NZ714547A (en) 2021-11-26
CN105555293B (zh) 2021-08-03
US10633639B2 (en) 2020-04-28
EP3003348A1 (en) 2016-04-13
CN105555293A (zh) 2016-05-04
JP6674603B2 (ja) 2020-04-01
MX368441B (es) 2019-10-02

Similar Documents

Publication Publication Date Title
PH12018550020A1 (en) Production of human milk oligosaccharides in microbial hosts with engineered import/export
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
ZA201507671B (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
MX2014011066A (es) Moleculas de union novedosas con actividad antitumoral.
MX2022010376A (es) Polipeptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamiferos.
BR112015029776A2 (pt) proteína quimérica, complexo proteico oligomérico, polinucleotídeo, vetor, célula transgênica, composição farmacêutica, método de produção da proteína quimérica, método para produzir um anticorpo, método de redução da carga bacteriana, método de indução de resistência, vacina, uso da proteína quimérica, anticorpo policlonal, método de prevenção e uso do anticorpo
NZ719654A (en) Interleukin-2 fusion proteins and uses thereof
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
BR112016002614B8 (pt) Imunocitoquina e composição farmacêutica
MX2016003945A (es) Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias.
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
BR112018010937A2 (pt) composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
BRPI0807710A8 (pt) Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112019000621A2 (pt) anticorpos tgfss, métodos e usos
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2013002379A (es) Moleculas de union a vegf.
MX2015005384A (es) Miembros de union para il-1 beta.
WO2014025199A3 (ko) 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
BR112016030950A2 (pt) polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
EP3674321A3 (en) Anti-met antibodies and uses thereof
BR112015009467A2 (pt) polinucleotídeo isolado que codifica uma proteína dgat1 quimérica, uso de uma célula,célula de planta, planta, parte de planta, propágulo ou progênie, proteína dgat1 quimérica, seu método de produção, e insumo animal ou para biocombustível

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: INMUNOVA S.A. (AR)

B25A Requested transfer of rights approved

Owner name: INMUNOVA S.A. (AR) ; CONSEJO NACIONAL DE INVESTIGA

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2014, OBSERVADAS AS CONDICOES LEGAIS